Ratings VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Market Closed - Nasdaq Other stock markets 04:00:00 2023-11-27 pm EST			5-day change	1st Jan Change
3.970 ^USD	-1.00%		+0.51%	+47.04%

Nov. 13	Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000	MT
Nov. 13	VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company has insufficient levels of profitability.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector : Pharmaceuticals

	1st Jan change	Capi. (M$)	ESG Refinitiv
VYNE THERAPEUTICS INC.	+47.04%	55 M $	C-
ELI LILLY AND COMPANY	+61.69%	532 B $	C+
NOVO NORDISK A/S	+47.80%	464 B $	B
JOHNSON & JOHNSON	-14.36%	364 B $	C+
ABBVIE INC.	-13.93%	246 B $	C+
ROCHE HOLDING AG	-19.35%	216 B $	A+
NOVARTIS AG	+2.60%	201 B $	B-
ASTRAZENECA PLC	-11.70%	195 B $	B+
PFIZER, INC.	-41.18%	170 B $	C+
AMGEN INC.	+0.62%	141 B $	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes